Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Dale GL. Coated-platelets: an emerging component of the pro-coagulant response. J Thromb Haemost 2005; 3: 2185–2192.
-
2.
Alberio L, Safa O, Clemetson KJ, et al. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000; 95: 1694–1702.
-
3.
Kempton CL, Hoffman M, Roberts HR, et al. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol 2005; 25: 861–866.
-
4.
Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415: 175–179.
-
5.
Szasz R, Dale GL. Thrombospondin and fibrinogen bind serotonin-derivatized proteins on COAT-platelets. Blood 2002; 100: 2827–2831.
-
6.
Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost 2007; 5: 774–780.
-
7.
Graham JB, Buckwalter JA, Hartley LJ, et al. Canine hemophilia: observations on the course, the clotting anomaly, and the effect of blood transfusions. J Exp Med 1949; 90: 97–111.
-
8.
Brinkhous KM, Davis PD, Graham JB, et al. Expression and linkage of genes for X-linked hemophilias A and B in the dog. Blood 1973; 41: 577–585.
-
9.
Mustard JF, Secord D, Hoeksema TD, et al. Canine factor-VII deficiency. Br J Haematol 1962; 8: 43–47.
-
10.
Spurling NW, Peacock R, Pilling T. The clinical aspects of canine factor-VII deficiency including some case histories. J Small Anim Pract 1974; 15: 229–239.
-
11.
Callan MB, Aljamali MN, Margaritis P, et al. A novel missense mutation responsible for factor VII deficiency in research Beagle colonies. J Thromb Haemost 2006; 4: 2616–2622.
-
12.
Brinkhous KM, Read MS, Reddick RL, et al. Pathophysiology of platelet-aggregating von Willebrand factor: applications of the venom coagglutinin vWF assay. Ann N Y Acad Sci 1981; 370: 191–204.
-
13.
Lipscomb DL, Bourne C, Boudreaux MK. Two genetic defects in alphaIIb are associated with type I Glanzmann's thrombasthenia in a Great Pyrenees dog: a 14-base insertion in exon 13 and a splicing defect of intron 13. Vet Pathol 2000; 37: 581–588.
-
14.
Boudreaux MK, Catalfamo JL. Molecular and genetic basis for thrombasthenic thrombopathia in Otterhounds. Am J Vet Res 2001; 62: 1797–1804.
-
15.
Callan MB, Bennett JS, Phillips DK, et al. Inherited platelet delta-storage pool disease in dogs causing severe bleeding: an animal model for a specific ADP deficiency. Thromb Haemost 1995; 74: 949–953.
-
16.
Brooks MB, Catalfamo JL, Friese P, et al. Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mitochondrial depolarization. J Thromb Haemost 2007; 5: 1972–1974.
-
17.
Brooks MB, Randolph J, Warner K, et al. Evaluation of platelet function screening tests to detect platelet procoagulant deficiency in dogs with Scott syndrome. Vet Clin Pathol 2009; 38: 306–315.
-
18.
Brooks M. A review of canine inherited bleeding disorders: biochemical and molecular strategies for disease characterization and carrier detection. J Hered 1999; 90: 112–118.
-
19.
Alberio L, Friese P, Clemetson KJ, et al. Collagen response and glycoprotein VI function decline progressively as canine platelets age in vivo. Thromb Haemost 2002; 88: 510–516.
-
20.
Kotova YN, Ataullakhanov FI, Panteleev MA. Formation of coated platelets is regulated by the dense granule secretion of adenosine 5′diphosphate acting via the P2Y12 receptor. J Thromb Haemost 2008; 6: 1603–1605.
-
21.
Hamilton SF, Miller MW, Thompson CA, et al. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro. J Lab Clin Med 2004; 143: 320–326.
-
22.
Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82: 8752–8756.
-
23.
Brinkhous K, Sandberg H, Widlund L, et al. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin Thromb Hemost 2002; 28: 269–272.
-
24.
Nichols TC, Bellinger DA, Reddick RL, et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood 1993; 81: 2644–2651.
-
25.
Evans JP, Brinkhous KM, Brayer GD, et al. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A 1989; 86: 10095–10099.
-
26.
Herzog RW, Arruda VR, Fisher TH, et al. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony. Thromb Haemost 2000; 84: 352–354.
-
27.
Haberichter SL, Merricks EP, Fahs SA, et al. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood 2005; 105: 145–152.
-
28.
Olsen EH, McCain AS, Merricks EP, et al. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). Blood 2003; 102: 436–441.
-
29.
Read MS, Shermer RW, Brinkhous KM. Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor. Proc Natl Acad Sci U S A 1978; 75: 4514–4518.
-
30.
Hjelm H, Hjelm K, Sjoquist J. Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins. FEBS Lett 1972; 28: 73–76.
-
31.
Sorensen BB, Persson E, Freskgard PO, et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863–11868.
-
32.
Niiya K, Hodson E, Bader R, et al. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 1987; 70: 475–483.
-
33.
Italiano JE Jr, Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227–1233.
-
34.
Remenyi G, Szasz R, Friese P, et al. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol 2005; 25: 467–471.
-
35.
Brinkhous KM, Hedner U, Garris JB, et al. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A 1989; 86: 1382–1386.
-
36.
Weiss DJ, Brazzell JL. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2006; 20: 682–686.
-
37.
Klein MK, Dow SW, Rosychuk RA. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982–1987). J Am Vet Med Assoc 1989; 195: 246–250.
-
38.
Scott-Moncrieff JC, Treadwell NG, McCullough SM, et al. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2001; 37: 220–227.
-
39.
Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med 2002; 16: 504–509.
-
40.
Piek CJ, Junius G, Dekker A, et al. Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med 2008; 22: 366–373.
Advertisement
Development of a flow cytometric assay for detection of coated platelets in dogs and evaluation of binding of coated platelets to recombinant human coagulation factor VIIa
Abstract
Objective—To develop an antibody-based flow cytometric assay to detect coated platelets in dogs and to characterize the interaction of recombinant human coagulation factor VIIa with activated platelets from dogs with hemophilia A.
Sample—Platelets from 4 dogs with hemophilia A, 4 dogs with hemophilia B, 4 dogs with von Willebrand disease, and 6 hemostatically normal dogs.
Procedures—Freshly isolated platelets were activated with thrombin, convulxin, or a thrombin-convulxin combination. Resulting platelet phenotypes were resolved on the basis of P-selectin and fibrinogen expression, and binding of recombinant human coagulation factor VIIa to these distinct platelet subpopulations was measured by use of a flow cytometric assay.
Results—Coated platelets were identified on the basis of expression of α-granule fibrinogen and were generated in response to stimulation with the thrombin-convulxin combination but not to stimulation with either agonist alone. Approximately 70% of the platelets from dogs with hemophilia A, hemophilia B, and von Willebrand disease and from the control dogs had the coated platelet phenotype. Recombinant human coagulation factor VIIa bound preferentially to coated platelets with a mean ± SD binding equilibrium constant of 2.6 ± 0.5μM.
Conclusions and Clinical Relevance—Formation of coated platelets in dogs was similar to that in humans. Recombinant human coagulation factor VIIa bound preferentially to coated platelets from dogs.
Impact for Human Medicine—A similar mechanism of action for recombinant human coagulation factor VIIa may exist in dogs and humans. The potential for use of dogs in the study of bleeding disorders in humans was strengthened.
Contributor Notes
Supported by a grant from the National Institutes of Health (NIH/NHLBI R24HL063098-12). Dr. Knudsen was supported by the University of Copenhagen Faculty of Life Sciences; the Danish Ministry of Science, Technology and Innovation; and Novo Nordisk A/S.
The authors thank Lone Odborg, Robin Raymer, John Nowicki, and Victoria Hamlett for technical assistance and Drs. Bo Wiinberg, Mads Kjelgaard-Hansen, Hanne Gamst-Andersen, and Christopher Scull for technical advice.
Powered by PubFactory